So definitely there will be also quite price cuts because of the budget pressure in China. But AstraZeneca has very good coverage and a solid No. 1 position in China. So we will definitely be able to scale up volume much faster than the other companies in China. So we will definitely b...
“We are helping companies like AstraZeneca achieve deeper insight into their programs and trials with our unique cancer expertise and our ability to provide genomic information that can impact clinical treatment decisions,” Michael Pellini, president and CEO of Foundation Medicine, said in a statemen...